'Very re­al' head­winds: With lean­er staff, can­cer vac­cine mak­er search­es for help

Can­cer vac­cine biotech IMV said it will look at “strate­gic al­ter­na­tives fol­low­ing a re­view of its busi­ness” as the Cana­di­an com­pa­ny con­tin­ues clin­i­cal tri­als.

The No­va Sco­tia and Cam­bridge, MA biotech laid off about one-third of its staff last fall to “max­i­mize share­hold­er val­ue.” Now, IMV wants to “re­al­ize its full clin­i­cal po­ten­tial” in sol­id and hema­to­log­ic can­cers and has tapped Stonegate Health­care Part­ners to fig­ure that out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER